Enhertu shows positive results in DESTINY-Breast06 Phase III trial
Demonstrates statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
ENHERTU
Blockbuster Enhertu may get tumor agnostic label, targeting any HER2-expressing cancer: GlobalData
GlobalData’s consensus forecast projects global sales for Enhertu to reach $9.9 billion by 2028
Enhertu improves both progression-free and overall survival in Destiny-Breast04 trial in patients…
First HER2-low metastatic breast cancer phase-III results for AstraZeneca and Daiichi Sankyo’s Enhertu offer potential to redefine…
US FDA grants priority review to Daiichi Sankyo and AstraZeneca’s sBLA of Enhertu
Enhertu is a HER2-directed Antibody Drug Conjugate (ADC) being jointly developed by Daiichi Sankyo and AstraZeneca for treatment…
ENHERTU (fam-trastuzumab deruxtecan-nxki) gets US FDA nod for HER2-positive advanced gastric cancer
The results from the DESTINY-Gastric01 trial showed a 41 per cent improvement in survival and a response rate more than three…